DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Morgan Stanley - 2 Ulz - 2 Michael Ulz - 1 Kyverna - 1 Jason Gerberry - 1 Michael Ulz's - 1 Gerberry - 1 Rejuva - 1
Top related locs:
KYV Kyverna Fractyl
Top related orgs:
Therapeutics - 1 Nasdaq - 1 autoimmunity - 1 Bank of America - 1 Evercore ISI - 1 Fractyl's - 1 Bank - 1 America's - 1

Search resuls for: "Michael Ulz"


3 mentions found


☆ Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
  + stars: | 2024-03-04 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. The stock opened at $34.25, above the initial public offering price of $22 per share, and closed Friday at $27.75. Although the data from KYV-101 is limited, Ulz wrote that he's "highly encouraged given promising results across multiple indications, multiple sites, and in challenging patients." The analyst pointed out that cell therapies have "meaningfully improved" the treatment of B-cell cancers and that multiple therapies are currently approved, increasing the therapies' potential to treat autoimmune diseases. Ingenui-T is a next-generation process in preclinical development for manufacturing autologous anti-CD19 CAR T-cell therapy, and uses the same CAR construct as KYV-101, Kyverna said.
Persons: Morgan Stanley, Michael Ulz, Kyverna, Ulz Organizations: Therapeutics, Nasdaq, autoimmunity Locations: KYV, Kyverna
☆ Wall Street thinks this revolutionary gut health stock can triple in value
  + stars: | 2024-02-27 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +4 min
Just weeks after its initial public offering, Fractyl Health is catching Wall Street's attention as the next potential biopharmaceutical darling. Analysts are highlighting the company's groundbreaking therapies that directly target the gut and pancreas to ultimately induce Type 2 diabetes maintenance and weight loss. "Growing evidence indicates the gut is a core regulator of metabolism, placing gut dysfunction as a root cause of metabolic disease. Indeed, emerging consensus links modern diets to changes in the gut and pancreas that in turn increase an individual's risk of developing Type 2 Diabetes and obesity," Ulz wrote. gut) root cause of disease, could result in a more durable, disease-modifying treatment, differentiated from current, more burdensome (i.e.
Persons: Morgan Stanley, Jason Gerberry, Michael Ulz's, Ulz, Gerberry, Rejuva, America's Gerberry Organizations: Bank of America, Evercore ISI, Fractyl's, Bank, America's Locations: Fractyl
☆ Morgan Stanley sees this gene therapy stock doubling from here
  + stars: | 2023-02-01 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Rocket Pharmaceuticals could soar as a trial with blockbuster sales potential enters a pivotal phase, according to Morgan Stanley. Analyst Michael Ulz initiated the stock at overweight with a $45 price target. That target share price implies the stock will rally 107.1% from Tuesday's close. Ulz called Rocket a "leading gene therapy company" that can find the best treatments for a given disease. RP-A501, a one-time gene therapy treatment, has shown "promising" phase one results among adults and children, Ulz said.
0 next >>
Total: 3